Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 4680

1.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
2.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
4.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
5.

Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder.

Christman AK, Fermo JD, Markowitz JS.

Pharmacotherapy. 2004 Aug;24(8):1020-36. Review.

PMID:
15338851
6.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

7.

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.

Clin Ther. 2007 Jun;29(6):1168-77.

PMID:
17692731
8.

Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Simpson D, Plosker GL.

Drugs. 2004;64(2):205-22. Review.

PMID:
14717619
9.

Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

CNS Drugs. 2010 Jan;24(1):85-8. doi: 10.2165/11203670-000000000-00000. Review.

PMID:
20030421
10.

Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.

Corman SL, Fedutes BA, Culley CM.

Am J Health Syst Pharm. 2004 Nov 15;61(22):2391-9. Review.

PMID:
15581262
11.

Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Simpson D, Plosker GL.

CNS Drugs. 2004;18(6):397-401. Review.

PMID:
15089111
13.

Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.

[No authors listed]

Prescrire Int. 2010 Feb;19(105):5-8.

PMID:
20455329
14.

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.

Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE, Sutton VK, Gonzales J, Malcolm SK, Schuh KJ, Allen AJ.

Pediatrics. 2004 Jul;114(1):e1-8.

PMID:
15231966
15.

Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis.

Cheng JY, Chen RY, Ko JS, Ng EM.

Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16.

PMID:
17572882
16.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Findling RL.

Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Review.

PMID:
18555941
17.

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J.

J Am Acad Child Adolesc Psychiatry. 2007 Feb;46(2):242-51.

PMID:
17242628
19.

[Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].

Davids E, Gastpar M.

Fortschr Neurol Psychiatr. 2004 Oct;72(10):586-91. German.

PMID:
15472782
20.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923

Supplemental Content

Support Center